Patheon NV (PTHN) Given Consensus Rating of “Hold” by Brokerages
Shares of Patheon NV (NASDAQ:PTHN) have received a consensus rating of “Hold” from the ten brokerages that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and one has assigned a buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $33.25.
Several research firms have recently commented on PTHN. BidaskClub cut shares of Patheon NV from a “sell” rating to a “strong sell” rating in a report on Saturday, September 2nd. Jefferies Group LLC reiterated a “hold” rating and issued a $35.00 price objective on shares of Patheon NV in a report on Friday, July 21st. Zacks Investment Research cut shares of Patheon NV from a “buy” rating to a “hold” rating in a report on Thursday, June 15th. Leerink Swann cut shares of Patheon NV from an “outperform” rating to a “market perform” rating and upped their price objective for the stock from $31.00 to $35.00 in a report on Friday, June 9th. Finally, Raymond James Financial, Inc. cut shares of Patheon NV from an “outperform” rating to a “mkt perform” rating in a report on Friday, June 9th.
Patheon NV (NASDAQ PTHN) remained flat at $34.98 during trading on Friday. The company’s stock had a trading volume of 229,751 shares. The company has a market capitalization of $5.08 billion and a P/E ratio of 44.85. The company’s 50 day moving average is $34.98 and its 200 day moving average is $34.98. Patheon NV has a 52-week low of $24.45 and a 52-week high of $35.02.
Large investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. acquired a new position in Patheon NV in the second quarter worth about $119,000. Seven Eight Capital LP acquired a new position in Patheon NV in the second quarter worth about $136,000. Pacad Investment Ltd. acquired a new position in Patheon NV in the second quarter worth about $164,000. Utah Retirement Systems acquired a new position in Patheon NV in the second quarter worth about $212,000. Finally, Amalgamated Bank acquired a new position in Patheon NV in the second quarter worth about $222,000.
Patheon NV Company Profile
Patheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company’s segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products.
Receive News & Ratings for Patheon NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Patheon NV and related companies with MarketBeat.com's FREE daily email newsletter.